An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects

Abstract

Purpose: Evaluate the safety and effectiveness of bimatoprost 0.03% for treatment of eyelash hypotrichosis in a pediatric population.

Patients and methods: This multicenter, randomized, double-masked, parallel-group study was conducted at seven sites in the US and Brazil. Subjects with eyelash hypotrichosis caused by chemotherapy or alopecia areata (aged 5-17 years) or healthy adolescents aged 15-17 years were enrolled (N=71). Subjects applied bimatoprost 0.03% or vehicle to upper eyelid margins once nightly for 4 months and were followed for 1 month post-treatment. Eyelash prominence was assessed using the validated 4-grade Global Eyelash Assessment scale with photonumeric guide. Changes in eyelash length, thickness, and darkness were measured by digital image analysis. Safety was assessed by adverse events and ophthalmic observations.

Results: Eyelash prominence improved in a significantly greater proportion of subjects treated with bimatoprost compared with vehicle at month 4 (70.8% versus 26.1%; P<0.001). This benefit was sustained at month 5 post-treatment assessment. Digital image analysis measures were significantly improved with bimatoprost. Significant treatment benefits with bimatoprost versus vehicle were evident among the healthy adolescents but not in the postchemotherapy or alopecia areata subgroups. The safety profile of bimatoprost was consistent with previous studies in adults.

Conclusion: Bimatoprost was safe and well tolerated in pediatric subjects with eyelash hypotrichosis. In this study with limited sample size, subgroup analyses showed that treatment was effective in healthy adolescents with no concurrent contributing medical condition, but not in those with eyelash hypotrichosis due to chemotherapy or alopecia areata.

Keywords: Latisse; adolescent; child; hypotrichosis.

Figure 1

Percentage of pediatric subjects with at least a 1-grade improvement from baseline in Global Eyelash Assessment scores. Notes: (A) Overall population. (B) Healthy adolescents. (C) Postchemotherapy pediatric subjects. (D) Pediatric subjects with alopecia areata. Study treatment was applied once nightly for 4 months. Subjects did not use study treatment between months 4 and 5. *P=0.004 versus vehicle. **P<0.001 versus vehicle.

Figure 2

Examples of response to bimatoprost treatment with a 1-grade improvement in GEA score from baseline to month 4. Notes: In a healthy subject aged 17 years, GEA score at baseline was 3 (A) and improved to GEA score of 4 at month 4 (B). In a postchemotherapy subject aged 13 years, baseline GEA score of 2 (C) improved to GEA score of 3 at month 4 (D). Abbreviation: GEA, Global Eyelash Assessment.

Figure 3

Responses to the ESQ-3 at month 4 for (A) satisfaction with eyelash length, (B) satisfaction with eyelash fullness/thickness, and (C) overall eyelash satisfaction for the overall pediatric population aged 12–17 years. Notes: Study treatment was applied once nightly for 4 months; subjects did not use study treatment between months 4 and 5. Abbreviation: ESQ-3, 3-item Eyelash Satisfaction Questionnaire.